Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a large decline in short interest during the month of March. As of March 31st, there was short interest totalling 236,400 shares, a decline of 9.6% from the March 15th total of 261,500 shares. Based on an average trading volume of 88,300 shares, the days-to-cover ratio is presently 2.7 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. UBS Group AG raised its position in shares of Enlivex Therapeutics by 73.4% in the third quarter. UBS Group AG now owns 31,871 shares of the company’s stock valued at $136,000 after purchasing an additional 13,490 shares during the period. Bank of America Corp DE increased its holdings in Enlivex Therapeutics by 87.0% during the 1st quarter. Bank of America Corp DE now owns 6,163 shares of the company’s stock worth $34,000 after acquiring an additional 2,867 shares during the period. Jane Street Group LLC lifted its stake in Enlivex Therapeutics by 89.6% in the 1st quarter. Jane Street Group LLC now owns 52,507 shares of the company’s stock worth $294,000 after purchasing an additional 24,807 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new position in Enlivex Therapeutics in the 1st quarter valued at $68,000. 1.02% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright decreased their price objective on shares of Enlivex Therapeutics from $12.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, April 12th.

Enlivex Therapeutics Stock Up 2.1 %

ENLV stock traded up $0.03 during midday trading on Wednesday, hitting $1.48. The company’s stock had a trading volume of 373,238 shares, compared to its average volume of 167,623. Enlivex Therapeutics has a 1 year low of $1.15 and a 1 year high of $4.59. The stock’s 50-day moving average price is $3.41 and its 200 day moving average price is $2.55.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.